CRNX vs SUPN
CRNX: A commercial-stage endocrine pharmaceutical company with a first-in-class oral GPCR-targeted therapy for acromegaly and a deep pipeline of programs across multiple endocrine diseases. SUPN: A neuroscience-focused biopharmaceutical company dedicated to developing and commercializing innovative therapies for complex central nervous system disorders.
Side-by-side fundamentals
| Metric | CRNX | SUPN | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $83.63 | $46.98 | |
| Market cap as of 2026-07-31 | $8.9B | $2.7B | |
| PEG as of 2026-07-31 | -0.47 | n/a | |
| Net margin as of 2026-07-31 | -2747.2% | -3.7% | SUPN higher |
| Gross margin as of 2026-07-31 | +86.0% | +89.7% | SUPN higher |
| Operating margin as of 2026-07-31 | -3020.3% | -7.8% | SUPN higher |
| ROE as of 2026-07-31 | -44.0% | -2.7% | SUPN higher |
| ROA as of 2026-07-31 | -39.6% | -2.0% | SUPN higher |
| Debt / equity as of 2026-07-31 | 0.00 | 0.00 | Tie |
| Revenue growth (YoY) as of 2026-07-31 | +2277.5% | +16.3% | CRNX higher |
| Revenue CAGR (3y) SEC XBRL | n/a | +2.5% | |
| Beta as of 2026-07-31 | 1.10 | 0.56 | |
| 1-year return as of 2026-07-30 close | +186.1% | +39.9% | CRNX higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.